Independent research on the U.S. markets, Baptista Research

Baptista Research

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. 

We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

Bausch Health Companies / Equity Bottom-Up

<ul><li>Bausch Health Companies Inc. showed positive momentum in its Q1 2025 financial results.</li><li>The company, which excludes Bausch & Lomb from this discussion, reported notable year-over-year revenue growth of 6% on a reported basis and 7% on an organic basis, alongside a 14% increase in adjusted EBITDA, reflecting a consistent upward trend as they celebrate their eighth consecutive quarter of year-over-year growth.</li><li>The refinancing of $7.9 billion to extend near- and medium-term debts is a significant highlight, providing financial flexibility by extending maturities, which optimizes Bausch Health's capital structure.</li></ul>

Bausch Health Companies Inc. showed positive momentum in its Q1 2025 financial results.The company, which excludes Bausch & Lomb from this discussion, reported notable year-over-year revenue growth of 6% on a reported basis and 7% on an organic basis, alongside a 14% increase in adjusted EBITDA, reflecting a consistent upward trend as they celebrate their eighth consecutive quarter of year-over-year growth.The refinancing of $7.9 billion to extend near- and medium-term debts is a significant highlight, providing financial flexibility by extending maturities, which optimizes Bausch Health's capital structure.

Bausch Health Companies Inc.: Can Solta’s 136% Surge in South Korea Make It a Global Aesthetics Powerhouse?